MDT-AP-0819
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 51.239999999999995
- os_event
- false
- age_years
- 7
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.071148196
- umap2_2d
- 5.209191266
- umap1_3d
- 3.278563911
- umap2_3d
- -1.158376794
- umap3_3d
- -3.343946108
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.120
- NOTCH_SIGNALING+0.090
- PANCREAS_BETA_CELLS+0.070
- HEME_METABOLISM+0.050
- PEROXISOME+0.020
- PI3K_AKT_MTOR_SIGNALING+0.020
- DNA_REPAIR+0.010
- KRAS_SIGNALING_DN+0.010
- WNT_BETA_CATENIN_SIGNALING-0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- E2F_TARGETS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- INTERFERON_GAMMA_RESPONSE-0.470
- G2M_CHECKPOINT-0.460
- IL6_JAK_STAT3_SIGNALING-0.440
- INFLAMMATORY_RESPONSE-0.440
- ALLOGRAFT_REJECTION-0.410
- APOPTOSIS-0.410
- TNFA_SIGNALING_VIA_NFKB-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1120 | Med | Medulloblastoma | 0.920 |
| 2 | MDT-AP-1115 | Med | Medulloblastoma | 0.909 |
| 3 | MDT-AP-1405 | Med | Medulloblastoma | 0.899 |
| 4 | MDT-AP-2017 | Med | Medulloblastoma | 0.894 |
| 5 | SRR1797238 | — | cohortSC | 0.889 |
| 6 | MDT-AP-0364 | Med | Medulloblastoma | 0.888 |
| 7 | MDT-AP-0029 | Med | Medulloblastoma | 0.885 |
| 8 | SRR1329334 | GTEX | — | 0.878 |
| 9 | MNG851 | — | — | 0.875 |
| 10 | MDT-AP-0153 | Med | Medulloblastoma | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |